JJIJ
GYRE icon

Johnson & Johnson Innovation - JJDC’s Gyre Therapeutics GYRE Stock Holding History

Johnson & Johnson Innovation - JJDC’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$290K Hold
8,927
– – 0.03% 18
2021
Q1 		$337K Hold
8,927
– – 0.04% 15
2020
Q4 		$422K Hold
8,927
– – 0.05% 14
2020
Q3 		$288K Hold
8,927
– – 0.06% 14
2020
Q2 		$393K Hold
8,927
– – 0.08% 12
2020
Q1 		$293K Hold
8,927
– – 0.16% 10
2019
Q4 		$456K Buy
+8,927
New +$374K 0.16% 9

Other funds holding GYRE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's GYRE Position: Q2 2021 in Review

Johnson & Johnson Innovation - JJDC held its Gyre Therapeutics (GYRE) position steady in Q2 2021 at 8,927 shares worth $290K. The position accounts for 0.03% of the portfolio, ranked #18.

Johnson & Johnson Innovation - JJDC first reported a position in GYRE in Q4 2019 and has held it in 7 quarters since. The position peaked at $456K in Q4 2019. 69 funds tracked by Wall St. Rank hold GYRE as of Q2 2021.

  • Johnson & Johnson Innovation - JJDC held 8,927 shares of Gyre Therapeutics worth $290K as of Q2 2021.
  • Johnson & Johnson Innovation - JJDC left its Gyre Therapeutics share count unchanged in Q2 2021.
  • Gyre Therapeutics made up 0.03% of Johnson & Johnson Innovation - JJDC's portfolio in Q2 2021, its #18 holding.
  • Johnson & Johnson Innovation - JJDC first reported a position in Gyre Therapeutics in Q4 2019 and has held it in 7 quarters since.
  • Johnson & Johnson Innovation - JJDC's Gyre Therapeutics position peaked at $456K in Q4 2019.
  • 69 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2021.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q2 2021, filed 3 Aug 2021.